…ical testing of an embryonic stem cell-based therapy for patients with insulin-dependent diabetes. Meanwhile, Bluebird Bio Inc. will use a $9.3 million grant to support a Phase I/II study to evaluate the safety and efficacy of LentiGlobin,...
Through its Common Fund the NIH has established the Center for Regenerative Medicine (NIH CRM), to s
IMAGES-002-HOUSE_OVERSIGHT_013483.txt
p.1
View source release ↗